

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2023

The Board announces that the AGM Resolutions as set out in the AGM Notice were duly passed by the Shareholders by way of poll at the AGM held on June 26, 2023.

References are made to the circular (the “**AGM Circular**”) and notice of annual general meeting (the “**AGM Notice**”) issued by the 3D Medicines Inc. (the “**Company**”) dated June 2, 2023 in connection with the annual general meeting (the “**AGM**”). Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the AGM Circular.

POLL RESULTS OF THE AGM

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce the poll results of the AGM held at Units 5906-5912, 59/F, The Center, 99 Queen’s Road Central, Hong Kong on Monday, June 26, 2023 at 10:00 a.m..

The AGM was presided over by Dr. Gong Zhaolong, the Chairman of the Company.

The total number of issued Shares of the Company as at the date of the AGM was 256,057,000 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against all the resolutions proposed at the AGM. There was no Share of the Company entitling the Shareholders to attend but vote only against the resolutions proposed at the AGM. No Shareholder was required to abstain from voting on the resolutions proposed at the AGM and no Shareholder has stated their intention to vote against the resolutions proposed at the AGM or to abstain from voting.

Tricor Investor Services Limited (the Hong Kong branch share registrar of the Company) acted as the scrutineer for counting of votes at the AGM.

The Board is pleased to announce that all the resolutions (the “**AGM Resolutions**”) as set out in the AGM Notice have been duly passed by the Shareholders by way of poll at the AGM and the details of poll results are as follows:

Ordinary Resolutions		No. of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company for the year ended December 31, 2022 and the reports of the Directors and auditor thereon.	51,993,264 100.00%	0 0.00%
2.	(a) To re-elect Dr. Gong Zhaolong as an executive Director.	51,993,264 100.00%	0 0.00%
	(b) To re-elect Mr. Zhu Pai as a non-executive Director.	51,993,264 100.00%	0 0.00%
	(c) To re-elect Mr. Zhou Feng as a non-executive Director.	51,993,264 100.00%	0 0.00%
	(d) To re-elect Ms. Chen Yawen as a non-executive Director.	51,993,264 100.00%	0 0.00%
	(e) To re-elect Dr. Li Jin as an independent non-executive Director.	51,993,264 100.00%	0 0.00%
	(f) To re-elect Dr. Lin Tat Pang as an independent non-executive Director.	51,993,264 100.00%	0 0.00%
	(g) To re-elect Mr. Liu Xinguang as an independent non-executive Director.	51,993,264 100.00%	0 0.00%
	(h) To authorise the Board to fix the remuneration of the Directors.	51,993,264 100.00%	0 0.00%
3.	To re-appoint Ernst & Young as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix their remuneration.	51,993,264 100.00%	0 0.00%
4.	(A) To give an issue mandate to the Directors to allot, issue and deal with additional shares in the Company not exceeding 20% of the total number of issued shares of the Company.	51,954,207 99.92%	39,057 0.08%
	(B) To give a repurchase mandate to the Directors to repurchase shares in the Company not exceeding 10% of the total number of issued shares of the Company.	51,993,264 100.00%	0 0.00%
	(C) To extend the general mandate granted to the Directors to allot, issue and deal with shares by the number of shares repurchased by the Company.	51,962,207 99.94%	31,057 0.06%

Ordinary Resolutions		No. of Votes (%)	
		For	Against
5.	To approve the adoption of the new share option scheme as set out in resolution numbered 5 of the AGM Notice.	51,954,207 99.92%	39,057 0.08%
6.	To approve the Scheme Mandate Limit (as defined in the new share option scheme) as set out in resolution numbered 6 of the AGM Notice.	51,954,207 99.92%	39,057 0.08%
7.	To approve the Category B Participant Limit (as defined in the new share option scheme) as set out in resolution numbered 7 of the AGM Notice.	51,954,207 99.92%	39,057 0.08%
8.	To approve the amendments of the restricted share unit scheme as set out in resolution numbered 8 of the AGM Notice.	51,983,172 99.98%	10,092 0.02%

As more than 50% of the votes were cast in favour of the AGM Resolutions, the AGM Resolutions were duly passed as ordinary resolutions of the Company.

Shareholders may refer to the AGM Notice of the Company for full text of the above resolutions.

Pursuant to Rule 13.39(5A) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), all the Directors attended the AGM in person.

ADOPTION OF SHARE OPTION SCHEME

According to the poll results of the AGM as set out above, the ordinary resolution approving the adoption of share option scheme, made in accordance with Chapter 17 of the Listing Rules and the principal terms of which are set out in the Company’s circular dated June 2, 2023, was duly passed by the Shareholders at the AGM.

By order of the Board
3D Medicines Inc.
Dr. GONG Zhaolong
Chairman of the Board and Executive Director

Hong Kong, June 26, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.